ReviewFrontiers in immunology2026
Interferon therapy for chronic hepatitis B in children: an immunological perspective.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic hepatitis B (CHB) remains a significant global health issue, particularly in children, where the virus can lead to long-term hepatic damage and immune system dysregulation. Interferon (IFN) therapy, such as pegylated interferon (PEG-IFN), has served as a fundamental approach in the management of CHB by facilitating immune modulation and viral suppression. Nevertheless, the application of this treatment in children presents unique challenges, including heterogeneous immune responses, potential adverse effects, and constraints regarding long-term efficacy. This perspective discusses the immunological mechanisms associated with IFN therapy in pediatric CHB, emphasizing its potential to enhance immune-mediated clearance and suppress viral activity. We additionally examine the primary clinical challenges, including treatment resistance, adverse effects, and the necessity for personalized approaches to optimize therapeutic outcomes. Furthermore, this study examines prospective developments in IFN therapy, encompassing innovations in drug formulations, combination treatment strategies, and the implementation of personalized medicine approaches. Despite the challenges associated with IFN therapy, it continues to be a promising treatment modality. Furthermore, ongoing research into its combination with other immunomodulatory agents holds potential for developing more effective and sustainable management strategies for children with CHB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.